1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2020, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.
Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 3 and 2 respectively.
Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Presbyopia - Overview
- Presbyopia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Presbyopia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Presbyopia - Companies Involved in Therapeutics Development
- Allergan Ltd
- Cellix Bio Pvt Ltd
- Eyenovia Inc
- Kedalion Therapeutics Inc
- Kubota Vision Inc
- Novartis AG
- Ocuphire Pharma Inc
- Orasis Pharmaceuticals Ltd
- Plex Pharmaceuticals Inc
- Presbyopia Therapies LLC
- Reven Pharmaceuticals Inc
- ViewPoint Therapeutics Inc
- Presbyopia - Drug Profiles
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- AGN-241622 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CAP-1160 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CLXOPH-561 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EV-06 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KT-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- oxymetazoline hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pilocarpine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RPEC-1004A - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule for Presbyopia and Cataract - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VP-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Presbyopia - Dormant Projects
- Presbyopia - Product Development Milestones
- Featured News & Press Releases
- Oct 10, 2019: Orasis Pharmaceuticals announces CSF-1 Eye Drop successfully met primary endpoint in phase 2b clinical study in Presbyopia
- Mar 27, 2019: Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia
- Nov 27, 2018: Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board
- Aug 02, 2018: Eye drop improves near vision in presbyopia patients
- May 05, 2016: Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia
- May 02, 2016: Encore Vision Announces Positive Results from the Phase I-II Study of Topical EV06 for the Treatment of Presbyopia
- Jan 25, 2016: Encore Vision Announces Completion of Target Enrollment
- Oct 05, 2015: Encore Vision Announces First Subject Enrolled in Study of Topical Treatment for Presbyopia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Presbyopia, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Presbyopia - Pipeline by Allergan Ltd, H1 2020
- Presbyopia - Pipeline by Cellix Bio Pvt Ltd, H1 2020
- Presbyopia - Pipeline by Eyenovia Inc, H1 2020
- Presbyopia - Pipeline by Kedalion Therapeutics Inc, H1 2020
- Presbyopia - Pipeline by Kubota Vision Inc, H1 2020
- Presbyopia - Pipeline by Novartis AG, H1 2020
- Presbyopia - Pipeline by Ocuphire Pharma Inc, H1 2020
- Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, H1 2020
- Presbyopia - Pipeline by Plex Pharmaceuticals Inc, H1 2020
- Presbyopia - Pipeline by Presbyopia Therapies LLC, H1 2020
- Presbyopia - Pipeline by Reven Pharmaceuticals Inc, H1 2020
- Presbyopia - Pipeline by ViewPoint Therapeutics Inc, H1 2020
- Presbyopia - Dormant Projects, H1 2020
List of Figures
- Number of Products under Development for Presbyopia, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allergan Ltd
- Cellix Bio Pvt Ltd
- Eyenovia Inc
- Kedalion Therapeutics Inc
- Kubota Vision Inc
- Novartis AG
- Ocuphire Pharma Inc
- Orasis Pharmaceuticals Ltd
- Plex Pharmaceuticals Inc
- Presbyopia Therapies LLC
- Reven Pharmaceuticals Inc
- ViewPoint Therapeutics Inc
